Take­da-part­nered Finch Ther­a­peu­tics grabs $36M and looks to leapfrog the pack in mi­cro­bio­me R&D

Close to a year af­ter Seres de­clared that it had jumped back on track af­ter a trou­bling set­back with its lead mi­cro­bio­me drug for Clostrid­i­um dif­fi­cile in­fec­tions, a dark horse in the pack is chal­leng­ing it for the lead in the emerg­ing field.

Four months af­ter merg­ing with Cresto­vo, Finch Ther­a­peu­tics has raised $36 mil­lion in Se­ries B mon­ey to hus­tle ahead with a mid-stage study of CP101 that got un­der­way last sum­mer. The “full spec­trum mi­cro­bio­ta” prod­uct was the main at­trac­tion for the merg­er, Finch CEO Mark Smith tells me, and re­placed their own ri­val ther­a­py in the pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER